Navigation Links
Cephalon First Quarter 2011 Earnings Conference Call Tuesday, May 3, 2011 at 5:00 p.m. EDT
Date:4/6/2011

FRAZER, Pa., April 6, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) has scheduled its regular quarterly earnings conference call covering first quarter 2011 results for 5:00 p.m. EDT on Tuesday, May 3, 2011. May 3, 2011 Schedule4:10 p.m. EDT

Q1 2011 results will be distributed by PRNewswire4:50 p.m. EDT

To participate in the conference call, dial 913-312-0867 and refer toConference Code Number 67208985:00 p.m. EDT

Conference call begins promptly. Simultaneous Webcast

Investors can listen to the call live by logging on to the company's website at www.cephalon.com and clicking on the "Investors" tab, then "Webcast." Please click on the link and follow the prompts for registration and access.

If you are unable to listen to the live broadcast, an audio or webcast replay of the call will be available approximately two hours after the event until 8 p.m. EDT, May 17, 2011.  To listen to the audio replay, dial 719-457-0820 and use the Conference Code Number 6720898.

Additional information presented on the conference call may be made available on the Investors page of the company's website.

Contact: Robert S. (Chip) Merritt
610-738-6376
cmerritt@cephalon.com

Joseph Marczely
610-883-5894
jmarczely@cephalon.com


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
2. Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D.
3. Cephalon Mourns the Passing of Founder, Chairman and CEO, Frank Baldino Jr., Ph.D.
4. Cephalon Announces Chairman and CEO to Remain on Medical Leave of Absence Indefinitely
5. Cephalon Reports Record Earnings and Raises 2010 Guidance
6. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
7. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
8. Cephalon Completes Acquisition of Arana Therapeutics
9. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
10. Cephalon Quarterly Conference Call Invitation
11. Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... York , March 22, 2017 ... largely fragmented, states a research report by Transparency Market ... Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted for ... 2015. The prominent players in this market are focusing ... their product portfolio, which is likely to lead to ...
(Date:3/22/2017)... ... ... Premier executive recruitment firm, Slone Partners, is proud to have been named a Top ... Hunt Scanlon Media is one of the most respected life science publications in the ... sector. , “It is a great honor for Slone Partners to be part of ...
(Date:3/22/2017)... , ... March 21, 2017 , ... The Conference Forum ... (CMO Summit) to be held on May 10-11, 2017, at the Colonnade Hotel in ... specifically for Chief Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical ...
(Date:3/22/2017)... and PETACH TIKVAH, Israel , March ... a leading developer of adult stem cell technologies for ... Chief Executive Officer, will provide an update on new ... nd Annual Neuroscience Biopartnering and Investment Forum, being ... York Academy of Sciences. ...
Breaking Biology Technology:
(Date:3/6/2017)... , March 6, 2017 ... sales technology, today announced Predictive Sales Coach TM ... infusing actionable sales intelligence into Salesforce. This unique ... enable their sales organizations with deep knowledge of ... allow for intelligent engagement. Predictive Sales Coach extends ...
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
Breaking Biology News(10 mins):